KD Logo

Investing in EyePoint Pharmaceuticals Inc (EYPT): What You Must Know

In a filing, EyePoint Pharmaceuticals Inc revealed its Director DICICCO WENDY F acquired Company’s shares for reported $19997.0 on Aug 20 ’24. In the deal valued at $7.79 per share,2,567 shares were bought. As a result of this transaction, DICICCO WENDY F now holds 9,967 shares worth roughly $80035.01.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, ANDO GORAN bought 5,000 shares, generating $39,750 in total proceeds. Upon buying the shares at $7.95, the Director now owns 13,150 shares.

Before that, Zaderej Karen L. bought 12,500 shares. EyePoint Pharmaceuticals Inc shares valued at $99,750 were divested by the Director at a price of $7.98 per share. As a result of the transaction, Zaderej Karen L. now holds 16,500 shares, worth roughly $0.13 million.

Jefferies initiated its EyePoint Pharmaceuticals Inc [EYPT] rating to a Buy in a research note published on August 28, 2024; the price target was $15. A number of analysts have revised their coverage, including JP Morgan’s analysts, who began to cover the stock in late January with a ‘”an Overweight”‘ rating. Mizuho began covering EYPT with “Buy” recommendation on November 02, 2023. Robert W. Baird started covering the stock on April 21, 2023. It rated EYPT as “an Outperform”.

Price Performance Review of EYPT

On Tuesday, EyePoint Pharmaceuticals Inc [NASDAQ:EYPT] saw its stock fall -2.55% to $8.03. Over the last five days, the stock has lost -1.53%. EyePoint Pharmaceuticals Inc shares have fallen nearly -65.25% since the year began. Nevertheless, the stocks have fallen -19.94% over the past one year. While a 52-week high of $30.99 was reached on 02/08/24, a 52-week low of $5.67 was recorded on 08/14/24. SMA at 50 days reached $8.85, while 200 days put it at $16.34.

Levels Of Support And Resistance For EYPT Stock

The 24-hour chart illustrates a support level at 7.64, which if violated will result in even more drops to 7.26. On the upside, there is a resistance level at 8.38. A further resistance level may holdings at 8.74. The Relative Strength Index (RSI) on the 14-day chart is 43.09, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.56, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 78.79%. Stochastics %K at 22.17% indicates the stock is a holding.

How much short interest is there in EyePoint Pharmaceuticals Inc?

A steep rise in short interest was recorded in EyePoint Pharmaceuticals Inc stocks on 2024-08-15, dropping by -0.6 million shares to a total of 9.48 million shares. Yahoo Finance data shows the prior-month short interest on 2024-07-15 was 10.08 million shares. There was a decline of -6.37%, which implies that there is a negative sentiment for the stock.

The most recent change occurred on July 07, 2022 when Chardan Capital Markets began covering the stock and recommended ‘”a Buy”‘ rating along with a $21 price target.

Most Popular